{"id":"W2903062212","doi":"10.1056/nejmoa1804980","title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4044,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Juravinski Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Cytokine release syndrome; Neutropenia; Internal medicine; Hematopoietic stem cell transplantation; Diffuse large B-cell lymphoma; Lymphoma; Refractory (planetary science); Transplantation; Gastroenterology; Febrile neutropenia; Rituximab; Clinical endpoint; Oncology; Phases of clinical research; Salvage therapy; Immunology; Immunotherapy; Chimeric antigen receptor; Chemotherapy; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}